IP Library Granted Patent US 12,024,514
Granted Patent B2
US 12,024,514 · App. 17/309,216 · Granted Jul 2, 2024

N-1 branched alkyl ether substituted imidazo[4,5-c]quinoline compounds, compositions, and methods

Inventors: George W. Griesgraber (Eagan, MN); Bryon A. Merrill (River Falls, WI); Michael J. Rice (Woodbury, MN)
Assignee: Solventum Intellectual Properties Company
C07D471/04A61K31/4745A61P37/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,024,514
App. No.
17/309,216
Granted
Jul 2, 2024
Kind
B2
Abstract

Imidazo[4,5-c]quinoline compounds having a substituent that is attached at the N−1 position by a branched group, single enantiomers of the compounds, pharmaceutical compositions containing the compounds, and methods of making the compounds are disclosed. Methods of use of the compounds as immune response modifiers, for inducing cytokine biosynthesis in humans and animals, and in the treatment of diseases including infectious and neoplastic diseases are also disclosed.

Claims (29)

1. A compound of Formula (II), or salt thereof:

wherein:

n is an integer of 0 or 1;

R is selected from the group consisting of halogen, hydroxy, alkyl, alkoxy, and —C(O)—O-alkyl;

R 1 is —X—O—Y where X is a C 1-3 alkylene and Y is a C 1-3 alkyl;

R 2 is selected from the group consisting of hydrogen, methyl, ethyl, n-propyl, n-butyl, —CH 2 OCH 3 , —CH 2 OCH 2 CH 3 , and —CH 2 CH 2 OCH 3 ;

R 3 is a C 1-4 alkyl, R 4 is a C 1-4 alkyl, or R 3 and R 4 are combined to form a ring of 3-7 carbon atoms optionally having one oxygen atom in the ring; and

R 5 is —H, —CH 3 , —F, or —OH.

2. The compound or salt of claim 1 , wherein R is selected from the group consisting of halogen, hydroxy, —C 1-12 alkyl, —C 1-12 alkoxy, and —C(O)—O—C 1-10 alkyl.

3. The compound or salt of claim 1 , wherein n is 0.

4. The compound or salt of claim 1 , wherein R 1 is —X—O—Y where X is —CH 2 —, —CH 2 CH 2 —, or —CH(CH 3 )— and Y is a C 1-3 alkyl.

5. The compound or salt of claim 1 , wherein Y is —CH 3 or —CH 2 CH 3 .

6. The compound or salt of claim 1 , wherein R 3 is a C 1-4 alkyl.

7. The compound or salt of claim 1 , wherein R 4 is a C 1-4 alkyl.

8. The compound or salt of claim 1 , wherein R 3 and R 4 are combined to form a ring of 3-7 carbon atoms optionally having one oxygen atom in the ring.

9. The compound or salt of claim 1 , wherein R 1 is —X—O—Y where X is —CH 2 — or —CH(CH 3 )— and Y is —CH 3 or —CH 2 CH 3 ; R 2 is selected from the group consisting of hydrogen, methyl, and ethyl; R 3 is a C 1-4 alkyl; R 4 is a C 1-4 alkyl; R 5 is —H, —CH 3 , or —OH; and n is 0.

10. The compound or salt of claim 9 , wherein the compound is (3R)-3-(4-aminoimidazo[4,5-c]quinolin-1-yl)-4-ethoxy-2-methyl-butan-2-ol.

11. The compound or salt of claim 9 , wherein the compound is (3R)-3-(4-amino-2-methyl-imidazo[4,5-c]quinolin-1-yl)-4-ethoxy-2-methyl-butan-2-ol.

12. The compound or salt of claim 9 , wherein the compound is (3R)-3-(4-amino-2-ethyl-imidazo[4,5-c]quinolin-1-yl)-4-ethoxy-2-methyl-butan-2-ol.

13. The compound or salt of claim 9 , wherein the compound is 1-[(1S)-1-(ethoxymethyl)-2,2-dimethyl-propyl]imidazo[4,5-c]quinolin-4-amine.

14. The compound or salt of claim 9 , wherein the compound is 1-[(1S)-1-(methoxymethyl)-2,2-dimethyl-propyl]imidazo[4,5-c]quinolin-4-amine.

15. The compound or salt of claim 9 , wherein the compound is (2R)-2-(4-aminoimidazo[4,5-c]quinolin-1-yl)-1-ethoxy-3-ethyl-pentan-3-ol.

16. The compound or salt of claim 9 , wherein the compound is (3R,4S)-3-(4-aminoimidazo[4,5-c]quinolin-1-yl)-4-ethoxy-2-methyl-pentan-2-ol.

17. The compound or salt of claim 1 , wherein R 1 is —X—O—Y where X is —CH 2 — or —CH(CH 3 )— and Y is —CH 3 or —CH 2 CH 3 ; R 2 is selected from the group consisting of hydrogen, methyl, and ethyl; R 3 and R 4 are combined to form a ring of 3-7 carbon atoms optionally having one oxygen atom in the ring; R 5 is —H, —CH 3 , or —OH; and n is 0.

18. The compound or salt of claim 17 , wherein the compound is 1-[(1R)-1-(4-aminoimidazo[4,5-c]quinolin-1-yl)-2-ethoxy-ethyl]cyclopentanol.

19. A pharmaceutical composition comprising an effective amount of a compound or salt of claim 1 in combination with a pharmaceutically acceptable carrier.

20. The pharmaceutical composition of claim 19 , further comprising an antigen.

21. A method of inducing cytokine biosynthesis in a human or animal comprising administering an effective amount of a compound or salt of claim 1 to the human or animal.

22. A method of treating a neoplastic disease in a human or animal by administering an effective amount of a compound or salt of claim 1 to the human or animal.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 1, 2024
From: 3M INNOVATIVE PROPERTIES COMPANY
To: SOLVENTUM INTELLECTUAL PROPERTIES COMPANY
Reel/Frame 066443/0600 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 7, 2021
From: GRIESGRABER, GEORGE W.; MERRILL, BRYON A.; RICE, MICHAEL J.
To: 3M INNOVATIVE PROPERTIES COMPANY
Reel/Frame 056170/0692 →
Continuity (2)
Provisional Application 62771229 · Nov 26, 2018
Related Publication 20210323962A1 · Oct 21, 2021